Kura Oncology KURA Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -443.5%-70.4pp | -449.9%-91.4pp | -377%+148pp | -390%+329pp | -373.2%+954pp | |
| Net margin | -411.2%-77.6pp | -412.9%-90.1pp | -340.9%+148pp | -350%+325pp | -333.6%+914pp | |
| Returns | ||||||
| Return on equity | -124.7%-82.9pp | -94.8%-51.9pp | -65.1%-18.8pp | -51.1%-11.8pp | -41.8%-4.5pp | |
| Return on invested capital | -149.3%-99.3pp | -241.7%-175pp | -86%-33.6pp | -64.6%-19.6pp | -50%-8.6pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×+0.1× | |
| Liquidity | ||||||
| Current ratio | 6.1×-1.9× | 6.1×-3.4× | 5.1×-6.4× | 6.2×-8.8× | 8.1×-8.6× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×+0.2× | 0.1×+0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $1.22-70.8% | $1.99-58.6% | $2.77-43.2% | $3.49-35.2% | $4.17-30.7% | |
| Valuation | ||||||
| Market capitalization | $942.78M+86.2% | $904.11M+33.5% | $768.16M-54.6% | $517.72M-70.0% | $532.98M-70.2% | |
| Price / sales | 13.2×+3.9× | 13.4×+0.8× | 12.1×-29.8× | 9.2×-54.9× | 9.8×-123× | |
| Price / book | 8.7×+7.3× | 5.2×+3.6× | 3.2×-0.8× | 1.7×-2.0× | 1.5×-2.1× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Kura Oncology's ratios come from?
- Every ratio is computed from Kura Oncology's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
